Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...

(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured ...